Logotype for ImmuCell Corporation

ImmuCell (ICCC) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for ImmuCell Corporation

Q2 2026 earnings summary

2 Sep, 2026

Executive summary

  • Revenue for Q2 2026 increased 11.5% year-over-year to $7.2 million, driven by higher sales volumes, price increases, and strong demand for First Defense®, with expanded market share and investments in leadership, sales, and manufacturing.

  • Net income for Q2 2026 rose to $1.8 million (25.5% margin), up from $0.5 million, aided by a $2 million legal settlement from a former contract manufacturer.

  • Distributor out-the-door volume grew 28% in Q2 2026, with Tri-Shield® and Functional Feed lines contributing to growth.

  • Commercial results benefited from restored product availability, expanded commercial team, and favorable domestic calf market conditions.

  • The company is executing a two-phase manufacturing expansion to triple capacity, with $8 million in planned investments over 18 months.

Financial highlights

  • Six-month revenue increased 20.9% year-over-year to $17.5 million; Q2 2026 product sales were $7.2 million, up from $6.4 million.

  • Gross margin declined to 33.9% from 43.7% in Q2 2025, mainly due to higher costs, lower output, and cost shifts.

  • Net income for the first six months was $3.8 million, nearly doubling year-over-year.

  • Adjusted EBITDA for Q2 2026 was $2.7 million, up from $1.4 million; six-month adjusted EBITDA was $5.4 million.

  • Cash and cash equivalents increased to $8.9 million as of June 30, 2026, from $3.8 million at year-end 2025; stockholders’ equity rose to $31.4 million.

Outlook and guidance

  • Capacity expansion projects totaling $8 million are expected to be completed in phases through 2027, aiming to triple capacity and improve costs.

  • Focus on yield improvement, cost management, and reliable supply to support scalable growth.

  • Ongoing investments in manufacturing are expected to support future demand growth for First Defense®.

  • No pending plans to issue additional shares under the ATM equity program as of June 30, 2026.

  • The company anticipates continued tax liability as NOLs now offset only 80% of taxable income.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ImmuCell